Relevant bibliographies by topics / Adjuvant 5-Fluorouracil

Academic literature on the topic 'Adjuvant 5-Fluorouracil'

Author: Grafiati
Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Adjuvant 5-Fluorouracil.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Adjuvant 5-Fluorouracil"

1

Nimeiri, Halla Sayed, Yang Feng, Paul J. Catalano, Neal J. Meropol, Bruce J. Giantonio, Elin R. Sigurdson, James A. Martenson, et al. "Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201—An updated survival analysis." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): e14711-e14711. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e14711.

Full text
Abstract:
e14711 Background: Postoperative adjuvant chemotherapy has been historically limited to single agent 5FU in stage II/III rectal cancer pts. This phase III trial evaluated differences between pts treated with adjuvant FOLFOX versus FOLFIRI versus FU alone in stage II/III rectal cancer. Methods: Eligibility: resectable (T3-4 N0,Tany N1-3) adenocarcinoma rectum ≤12cm from anal verge. Pts had the option to receive FU with pre or postoperative XRT (50.4Gy). Preoperative FU/XRT pts were randomized to adjuvant FOLFIRI (arm A), FOLFOX (arm B), FU/LV(arm C). Postoperative FU/XRT pts were randomized to adjuvant FOLFIRI (arm D), FOLFOX (arm E), FU/LV (arm F). Pts received 8 cycles. Overall survival (OS) was the primary endpoint. Secondary endpoints included toxicity, sphincter preservation and patterns of failure. Results: 225pts out of planned 3150 were enrolled (10/03 to 10/05). Data Monitoring Committee closed E3201 when the GI Intergroup developed an alternative trial with bevacizumab (E5204). 179 pts were randomized; (A:28, B:25, C:30, D:31, E:33, F:32). There was increased grade 3/4 toxicity, mainly diarrhea,in postoperative FU/XRT arms (D:39%), (E:28%), (F:48%). Twenty-two (12%) pts did not receive adjuvant therapy. At a median follow up of 7.4yrs, the five-year recurrence free rate was 69%. Median OS was 8.3 yrs. There was no statistical difference in OS between all randomized groups. Five-year OS in arms (A:B:C:D:E:F) were (73%, 83%, 83%, 73%, 78%, 73%) respectively. Conclusions: FOLFOX can be safely administered to rectal cancer pts following chemo radiation. Given limitations of early trial closure and small sample size, there was no difference in OS between pts who received FU alone, oxaliplatin based or irinotecan based adjuvant therapy. Clinical trial information: NCT00068692.
APA, Harvard, Vancouver, ISO, and other styles
2

Asaria, Riaz Hassan Yusuf, Chee Hing Kon, Catey Bunce, David G. Charteris, David Wong, Peng Tee Khaw, and George William Aylward. "Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy." Ophthalmology 108, no. 7 (July 2001): 1179–83. http://dx.doi.org/10.1016/s0161-6420(01)00589-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Amonkar, Sunil J., Henry J. Cain, Tracey Hughes, J. Diane Hemming, and David A. Browell. "Adjuvant 5-Fluorouracil-Induced Colitis Necessitating Completion Colectomy." Journal of Gastrointestinal Cancer 42, no. 4 (January 6, 2011): 275–77. http://dx.doi.org/10.1007/s12029-010-9241-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hill, GeorgeJ, L. Peter Fielding, Rosemary Hittinger, RogerH Grace, and JohnS Fry. "Adjuvant treatment with 5-fluorouracil for colorectal cancer." Lancet 340, no. 8831 (November 1992): 1349–50. http://dx.doi.org/10.1016/0140-6736(92)92530-s.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kizilbash, Sani Haider, Kevin Ward, Ishmael A. Jaiyesimi, and Joseph Lipscomb. "Survival outcomes in patients with early-stage, resectable pancreatic cancer: A comparison of gemcitabine and 5-fluorouracil based chemotherapy and chemoradiation regimens." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e14608-e14608. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14608.

Full text
Abstract:
e14608 Background: Beyond curative surgery, the optimal treatment for early stage pancreatic cancer is still a matter of debate. We conducted a comparative survival analysis between patients with resectable pancreatic cancer who received adjuvant treatment with either gemcitabine or 5-fluorouracil based chemotherapy and chemoradiation regimens. Methods: The Surveillance, Epidemiology and End Results (SEER)-Medicare database was used to identify patients with pancreatic cancer diagnosed from 1998 to 2005 who received curative surgery and adjuvant chemotherapy with either 5-fluorouracil or gemcitabine. These groups were subdivided by treatment with radiotherapy. Patients were followed until death, study endpoint or a maximum of five years after diagnosis. Results: 359 patients received 5-fluorouracil and 346 received gemcitabine. Compared to chemoradiation with 5-fluorouracil, outcomes for patients who received chemoradiation with gemcitabine did not differ. Patients who received gemcitabine without radiation had increased hazards (hazard ratio (HR) = 1.50 for high grade tumors (HGT), HR = 1.32 for low grade tumors (LGT)). However, outcomes of patients who received 5-fluorouracil without radiation varied with tumor grade. In LGT, patients had better outcomes with 5-fluorouracil when compared with chemoradiation with 5-fluorouracil (HR = 0.43). In HGT, the opposite was true (HR 2.10). Conclusions: Patients with low grade resectable pancreatic cancer may have better outcomes with 5-fluorouracil based chemotherapy without radiation when compared to 5-fluorouracil with radiation.
APA, Harvard, Vancouver, ISO, and other styles
6

Kelder, Wendy, Geke A. P. Hospers, and John T. M. Plukker. "Effects of 5-fluorouracil adjuvant treatment of colon cancer." Expert Review of Anticancer Therapy 6, no. 5 (May 2006): 785–94. http://dx.doi.org/10.1586/14737140.6.5.785.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Vaillant, Jean-Christophe, Bernard Nordlinger, Sylvie Deuffic, Jean-Pierre Arnaud, Edouard Pelissier, Jean-Pierre Favre, Daniel Jaeck, et al. "Adjuvant Intraperitoneal 5-Fluorouracil in High-Risk Colon Cancer." Annals of Surgery 231, no. 4 (April 2000): 449–56. http://dx.doi.org/10.1097/00000658-200004000-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Merendino, R. A., A. Ruello, S. Cascinu, B. Ferlazzo, A. Bene, D. Bonanno, P. Quattrocchi, N. Caristi, and S. Gangemi. "Influence of 5-Fluorouracil and Folinic Acid on Interleukin-18 Production in Colorectal Cancer Patients." International Journal of Biological Markers 17, no. 1 (January 2002): 63–66. http://dx.doi.org/10.1177/172460080201700108.

Full text
Abstract:
Aims and Background This study was carried out to evaluate the IL-18 blood concentrations of operated colorectal cancer patients and their possible variation in response to combination chemotherapy with 5-fluorouracil (5-FU) and folinic acid. Methods IL-18 levels were assayed in sera of 18 healthy donors and 18 surgical colorectal cancer patients before and after adjuvant chemotherapy with 5-fluorouracil and folinic acid. An ELISA kit for human IL-18 was used for the assay. Results Colorectal cancer patients showed significantly higher baseline levels of IL-18 than healthy donors (p<0.005). Furthermore, serum IL-18 levels increased significantly with respect to baseline in patients receiving adjuvant chemotherapy (p<0.005). Conclusions This study suggests that treatment with 5-fluorouracil and folinic acid may provoke an increase in IL-18 serum levels in colorectal cancer patients. This increase may help to explain the efficacy of adjuvant chemotherapy with 5-FU in colorectal cancer.
APA, Harvard, Vancouver, ISO, and other styles
9

Dencausse, Y., G. Hartung, J. Sturm, A. Kopp-Schneider, E. Hagmüller, C. Wojatschek, H. Lindemann, D. Fritze, and W. Queisser. "Adjuvant Chemotherapy in Stage III Colon Cancer with 5-Fluorouracil and Levamisole versus 5-Fluorouracil and Leucovorin." Oncology Research and Treatment 25, no. 5 (2002): 426–30. http://dx.doi.org/10.1159/000067436.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bertuccelli, Maurizio, Francesco Cartei, Alfredo Falcone, Salvatrice Campoccia, Aldo Sainato, Francesco Ducci, Stefano Moda, et al. "Postoperative Adjuvant Chemoradiotherapy for Rectal Cancer: Analysis of Acute and Chronic Toxicity." Tumori Journal 83, no. 2 (March 1997): 599–603. http://dx.doi.org/10.1177/030089169708300224.

Full text
Abstract:
Aims and background The aim of the study was to evaluate acute and chronic toxicity of combined postoperative standard radiation therapy to the pelvis and 5-fluorouracil plus levamisole in resectable rectal cancer. Methods Between July 1990 and September 1993, 58 patients with histologically confirmed adenocarcinoma of the rectum entered the prospective study. The schedule consisted of 5-fluorouracil, 450 mg/m2 i.v. for 5 days, and from day 28 5-fluorouracil, 450 mg/m2 i.v. weekly for 24 weeks, plus levamisole given orally at the dose of 150 mg every day for 3 days every 2 weeks for 6 months; radiotherapy (180 cGy/day) 5 days a week for a total dose of 45 Gy was administered from day 28. Results After the first cycle of chemotherapy (before radiotherapy), overall toxicity was mild. During chemoradiotherapy, dose-limiting toxicity was grade 3 diarrhea and proctitis, for which the combined treatment was interrupted for more than 7 cumulative days in 28 patients. During the 24 weeks of weekly 5-fluorouracil (after radiotherapy), no severe toxicity was reported. Three-year survival and progression-free survival were 65% and 50–55%, respectively. Conclusions Although adjuvant chemoradiotherapy is usually feasible, in our study toxicity was severe in a substantial proportion of patients, probably due to the schedule applied. We are evaluating the feasibility and toxicity of a combined treatment which includes 5-fluorouracil in continuous chronomodulated infusion during radiotherapy.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Adjuvant 5-Fluorouracil"

1

Edler, David. "Thymidylate synthase expression in colorectal cancer : its role as a prognostic factor and a predictive factor in adjuvant 5-fluorouracil-based chemotherapy /." Stockholm, 2001. http://diss.kib.ki.se/2001/91-628-4651-5/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Beare, Sandra Louise. "The capacity of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms to predict outcome after adjuvant cyclophosphamide, methotrexate and 5-fluorouracil in patients with early breast cancer." Thesis, University of Newcastle Upon Tyne, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.555994.

Full text
Abstract:
Thymidylate synthase (1YMS) catalyses the conversion of dUMP to TMP and is the target of 5-fluorouracil (5FU). Expression of 1YMS modulates sensitivity to 5FU and polymorphisms in the TYMS gene have been associated with expression and response to 5FU. Methylenetetrahydrofolate reductase (MTHFR) catalyses the reductive methylation of 5,10-methylenetetrahydrofolate, a critical component of the complex formed when 5FU binds and inhibits 1YMS. A polymorphism of MTHFR leads to a thermolabile enzyme with reduced activity, and may alter sensitivity to 5FU. The majority of studies examining the relationship between TYMS and MTHFR and response to 5FU have been carried out in Gl cancers with conflicting results. The aim of this study was to examine the relationship between TYMS and MTHFR polymorph isms, and 1YMS protein expression and outcome, in women with early breast cancer who received adjuvant cyclophosphamide, methotrexate and 5FU (CMF). DNA was extracted from archival tumour tissue blocks, using laser capture microdissection where appropriate, from eighty-six women who received CMF, and from blood samples from 190 women who received doxorubicin and cyclophosphamide (AC). TYMS polymorphisms were analysed using PCR and restriction fragment length polymorphism techniques. PCR products were analysed by high performance capillary polyacrylamide gel electrophoresis with fluorescence detection. The MTHFR polymorphism was analysed by pyrosequencing. 1YMS protein expression was measured in a subset of CMF patients using immunohistochemistry. For patients receiving CMF, carrying a TYMS 3R allele was associated with a significantly increased risk of relapse and death (DFS HR=5.1 [95% er 1.2-21.9], p=D.O'l ; OS HR=4.3 [95% Cl 1.0-18.5], p=0.03). The TSdel6 polymorphism appeared to have some association with DFS and OS, with the 6 bp insertion (+6) homozygotes having the best outcome (p=0.08 and p=0.07, respectively). Patients who were homozygous for both the 2R and +6 alleles had significantly longer DFS (HR=30.1 [95% Cl 0.4-2400], p=O.Ol) and OS (HR=30 [95% er 0.2-3600], p=0.02) compared to all others, and none relapsed or died during the follow up period. These findings were not observed in the AC patients, indicating the differences seen in the CMF patients were treatment related. 1YMS protein expression was not associated with outcome after CMF, nor did it correlate with TS VNTR genotype, suggesting that expression was not the mechanism underlying the association between genotype and outcome. No association was observed between MTHFR C677T genotype and outcome in either the CMF or AC treated patients. The TS VNTR and TSdel6 polymorph isms yielded a significant association with outcome, and the 2R2R-+6+6 diplotype selected a group of patients who had not relapsed or died during the follow up period. The TS VNTR-deI6 diplotype may select breast cancer patients who would benefit from adjuvant CMF chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
3

Cushing, Merta, and Thao Truong. "Efficacy and toxicity of capecitabine/oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) in adjuvant and metastatic treatment of colorectal cancer in patients at the Southern Arizona Veteran Affairs Health Care System." The University of Arizona, 2017. http://hdl.handle.net/10150/624166.

Full text
Abstract:
Class of 2017 Abstract
Objectives: To determine the efficacy and toxicity of fluorouracil/leucovorin/oxaliplatin (FOLFOX) versus capecitabine/oxaliplatin (XELOX) in the treatment of colorectal cancer (CRC) in the adjuvant (aCRC) and metastatic (mCRC) setting in Veterans at the Southern Arizona Veteran Affairs Health Care System (SAVAHCS). Methods: A retrospective chart review was conducted to collect efficacy and toxicity data. Subjects were included based on age, treatment setting and regimen in the preset 5-year period, and appropriate diagnosis via International Classification of Diseases-Revision 9 (ICD-9) codes. Efficacy was measured via 1-year disease-free survival (DFS) for aCRC, progression-free survival (PFS) for mCRC, and overall survival (OS) for both settings. Results: A total of 79 subjects were initially enrolled with 51 and 54 all-male subjects included in the efficacy and toxicity analysis, respectively. Mean range of age was 63-72 years old. Subjects were divided into four groups: FOLFOX aCRC (17) and mCRC (19), XELOX aCRC (10) and mCRC (8). No difference was found in 1-year DFS and OS between aCRC groups, and PFS between mCRC groups; a higher incidence of 1-year OS with FOLFOX in the mCRC setting was noted (p = 0.03). No difference was found in toxicity between FOLFOX and XELOX, except a higher incidence of hand-foot syndrome in XELOX (p = 0.0007). Conclusions: Efficacy between FOLFOX and XELOX in aCRC and mCRC is similar, while toxicity is slightly more prevalent in XELOX due to increased hand-foot syndrome incidence. These findings agreed with the results reported by prospective clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
4

TSTE, WOON YUEN KHEE KIM. "Cancer du sein : chimiotherapie adjuvante ; resultats a long terme d'une serie de patientes n+ traitees de 1978 a 1992 a la clinique sainte-catherine par cmf ou avcf adjuvant." Aix-Marseille 2, 1993. http://www.theses.fr/1993AIX20143.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

PARGA, NATHALIE. "La chimiotherapie adjuvante chez la femme non menopausee atteinte d'un cancer du sein avec envahissement ganglionnaire axillaire : etude de 107 cas traites et suivis a nantes." Nantes, 1994. http://www.theses.fr/1994NANT009M.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Quack, Henriette [Verfasser], Torsten [Akademischer Betreuer] Liersch, and Hendrik [Akademischer Betreuer] Wolff. "5-Fluorouracil-Spiegelbestimmung unter neoadjuvanter Radiochemotherapie und adjuvanter Chemotherapie beim lokal fortgeschrittenen Rektumkarzinom / Henriette Quack. Gutachter: Torsten Liersch ; Hendrik Wolff. Betreuer: Torsten Liersch." Göttingen : Niedersächsische Staats- und Universitätsbibliothek Göttingen, 2015. http://d-nb.info/1070686131/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

CHINCHILLA, ERIC VICTOR. "Chimiotherapie neo-adjuvante associant cisplatine carboplatine et 5-fluorouracile dans les carcinomes epidermoides de la tete et du cou : a propos de 31 cas." Clermont-Ferrand 1, 1994. http://www.theses.fr/1994CLF1M027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Junior, Samuel Aguiar. ""Valor prognóstico e preditivo da expressão imunoistoquímica de timidilato sintase em pacientes portadores de adenocarcinoma colorretal"." Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/5/5155/tde-26102005-151553/.

Full text
Abstract:
O objetivo do estudo foi estudar a expressão de timidilato sintase (TS) como fator preditivo para eficácia de quimioterapia adjuvante com 5-fluorouracil (5-FU) e como fator prognóstico para sobrevida em pacientes portadores de câncer colorretal. Trata-se de estudo retrospectivo em uma série de 114 pacientes com carcinoma colorretal estádios II ou III, distribuídos em dois grupos: 1)cirurgia exclusiva (n=61); 2)cirurgia seguida de quimioterapia com 5-FU (n=53). A expressão de TS foi determinada por imunoistoquímica. Observou-se que a expressão intratumoral de TS foi capaz de selecionar pacientes que se beneficiaram com emprego de quimioterapia adjuvante, mas não se mostrou como variável independente para risco de recidiva ou óbito
The purpose of this study was trying to assess the value of TS expression as a predictive factor in the efficacy of adjuvant chemotherapy in colorectal cancer, as well as its independent prognostic value for survival. It deals with a retrospective study that assesses a series of 114 individuals with high risk colorectal cancer, distributed into two different groups: 1)surgery alone (n=61); 2)surgery and 5-FU-based chemotherapy (n=53). TS expression was determined by immunohistochemistry. We observed that TS expression may select patients that benefit from adjuvant chemotherapy, but it was not shown as an independent variable for the risk of recurrence or death
APA, Harvard, Vancouver, ISO, and other styles
9

Quack, Henriette. "5-Fluorouracil-Spiegelbestimmung unter neoadjuvanter Radiochemotherapie und adjuvanter Chemotherapie beim lokal fortgeschrittenen Rektumkarzinom." Doctoral thesis, 2015. http://hdl.handle.net/11858/00-1735-0000-0022-5FD0-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Adjuvant 5-Fluorouracil"

1

McLeon, Kelly. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. Edited by SreyRam Kuy and Miguel A. Burch. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199384075.003.0011.

Full text
Abstract:
The landmark MOSAIC trial examined whether the addition of oxaliplatin to a postoperative adjuvant treatment regimen of fluorouracil and leucovorin affected disease-free survival from colon cancer. The MOSAIC trial established the efficacy of FOLFOX over 5-FU/LV as adjuvant treatment for stage III colon cancer and established FOLFOX4 as the reference standard for adjuvant treatment for stage III disease. This chapter describes the basics of the study, including funding, year study began, year study was published, study location, who was studied, who was excluded, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews other relevant studies and information, gives a summary and discusses implications, and concludes with a relevant clinical case.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Adjuvant 5-Fluorouracil"

1

Vokes, E. E., W. R. Panje, and R. R. Weichselbaum. "5-Fluorouracil modulation in head and neck cancer." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 54–57. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cellerino, R., A. Piga, L. Latini, V. Saba, E. Cesini, G. L. Cetto, R. Bascioni, G. Corradini, A. Fianchini, and E. Landi. "Preoperative 5-Fluorouracil in resectable colorectal cancer. Preliminary results of a prospective randomized trial." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 223–26. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Balana, C., J. Minguell, B. Massuti, A. Arrivi, and B. Sanchez. "Treatment of locally advanced head and neck cancer with Neo-Adjuvant Cisplatin (CDDP) and 5-Fluorouracil (5-FU) chemotherapy (CT)." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 76–79. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

de Cremoux, H., N. Azli, S. Voisin, I. Monnet, P. Ruffié, M. Riggi, L. Vergnes, J. Huet, J. C. Saltiel, and E. Cvitkovic. "Cisplatin, 5-Fluorouracil + Leucovorin and Vindesine, in non-small cell lung cancer : a phase II study." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 447–48. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fety, R., J. Vignoud, P. Cappelaere, A. Pineau, and P. Viau. "Pharmacokinetic study of Neo-Adjuvant chemotherapy combining Carboplatin, Cisplatin and 5-Fluorouracil in head and neck squamous cell carcinoma." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 389–91. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_94.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vokes, Everett E., D. J. Haraf, W. R. Panje, J. M. McEvilly, M. F. Kozloff, D. Goldman, N. Clendeninn, A. G. Tybor, M. Collier, and R. R. Weichselbaum. "Cisplatin, 5-Fluorouracil and high dose oral Leucovorin (PFL) with Methotrexate and Piritrexim as Neo-Adjuvant chemotherapy for head and neck cancer." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 58–60. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Clark, J., A. Dreyfuss, C. Norris, P. Busse, C. Beard, J. Lucarini, J. Andersen, D. Miller, D. Casey, and E. Frei. "Neo-Adjuvant Cisplatin, 5-Fluorouracil and high-dose Leucovorin for advanced head and neck cancer : response, toxicity, survival and comparison with historical controls." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 50–53. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vincent, M., F. Levi, B. Girodet, E. Laennec, P. Poirie, B. Guibert, J. M. Ardiet, A. Boisson, and L. Van-Straaten. "Circadian chemotherapy against stage IIIB-IV non-small-cell lung cancer (NSCLC) with 5-Fluorouracil (5-FU), folinic acid (FOL) and cisplatin (CDDP) via a multichannel programmable pump. Preliminary results." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 395–99. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_96.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Thiberville, L., C. Faure, J. Bouillard, J. Clavier, Ph David, J. P. Duhamel, J. Heintz, et al. "Faster response and survival advantage with Neo-Adjuvant Cisplatin and 5-Fluorouracil infusion versus Cisplatin and Bleomycin in advanced non-small cell lung cancer." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 449–53. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Urba, Susan, A. Forastiere, G. Wolf, and A. Thornton. "Neo-Adjuvant chemotherapy for organ preservation with high dose continuous infusion of Cisplatin, 5-Fluorouracil, and Mitoguazone for head and neck cancer : a preliminary report." In Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy, 23–24. Paris: Springer Paris, 1991. http://dx.doi.org/10.1007/978-2-8178-0782-9_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Adjuvant 5-Fluorouracil"

1

Kim, Yong-Jae, Jinseon Jeong, Ki-Young Sohn, Do Young Lee, Sun Young Yoon, and Jae Wha Kim. "Abstract 360: Therapeutic potential of EC-18 as a chemotherapy adjuvant for 5-fluorouracil-induced neutropenia." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-360.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kim, Yong-Jae, Jinseon Jeong, Ki-Young Sohn, Do Young Lee, Sun Young Yoon, and Jae Wha Kim. "Abstract 360: Therapeutic potential of EC-18 as a chemotherapy adjuvant for 5-fluorouracil-induced neutropenia." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-360.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Owusu-Brackett, N., S. Scott, E. Yuca, KW Evans, C. Tapia, and F. Meric-Bernstam. "Abstract P1-13-04: Efficacy of adjuvant 5-Fluorouracil in residual HER2-negative breast cancer following neoadjuvant chemotherapy." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p1-13-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Levine, M., A. Arnold, L. Kelleher, S. Lord, W. Hryniuk, J. Hrish, and M. Gent. "CANCER CHEMOTHERAPY AND THROMBOSIS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643203.

Full text
Abstract:
Malignant disease is recognized as a risk factor for venous thromboembolism. A number of recent reports have suggested that cancer chemotherapy may contribute to this risk, but it was not possible to separate the role of chemotherapy from the effects of the malignant disease. We are conducting a randomized trial to determine the optimal duration of adjuvant chemotherapy in women with Stage II breast carcinoma. These ambulatory patients, with negligible tumour burden, receive either 12 weeks of chemo-hormonal therapy (cyclophosphamide, methotrexate, 5 fluorouracil, vincristine, prednisone, adriamycin and tamoxifen) or 36 weeks of chemotherapy (cyclophosphamide, methotrexate, 5 fluorouracil, vincristine and prednisone). This study has provided us with an opportunity to evaluate the thrombogenic effects of chemotherapy since patients in the 12 week group, while off chemotherapy, can be compared directly to the patients in the other group who are still on chemotherapy. This allows the confounding influence of the malignant process to be circumvented. All patients undergo screening tests for thrombosis (impedance plethysmography and Doppler ultrasound) and routine clinical assessments. Suspected venous thrombosis is confirmed by venography and suspected pulmonary embolism by either pulmonary angiography or high probability ventilation perfusion scanning. There have been 11 episodes of venous thromboembolism to date among 191 patients of whom 164 have completed the first 36 weeks of study. There were 3 episodes in each group during the first 12 weeks. During the subsequent 24 weeks there have been no events in the group whose treatment was stopped and 5 events in the group still on treatment (p 0.03). These findings demonstrate that chemotherapy per se is an important risk factor for venous thromboembolism in patients with malignant disease.
APA, Harvard, Vancouver, ISO, and other styles
5

Musa, Nafisah, and Tin Wui Wong. "Nanoparticles-in-soft microagglomerates as oral colon-specific cancer therapeutic vehicle." In 3rd International Congress of Engineering Sciences and Technology. Facultad de Ciencias de la Ingenierí­a y Tecnología, 2021. http://dx.doi.org/10.37636/recit.cicitec21.1.

Full text
Abstract:
Polymeric nanoparticles can be conjugated with targeting ligand such as folate to elicit oral colon-specific drug delivery to treat colon cancer. Oral chemotherapy can be used as adjuvant, neo-adjuvant, or primary therapy. Nonetheless, oral cancer chemotherapeutics may experience premature drug release at the upper gastrointestinal tract due to the availability of a large specific dissolution surface area of nanoparticles leading to failure in colon cancer targeting. This study designed soft microagglomerates as carrier of nanoparticles to delay drug release. High molecular weight chitosan/pectin with covalent 5-fluorouracil/folate was processed into nanoparticles. Low molecular weight chitosan was spray-dried into nanoparticle aggregation vehicle. The soft agglomerates were produced by blending of nanoparticles and aggregation vehicle in specific weight ratios through vortex method. Adding aggregation vehicle promoted soft agglomeration with nanoparticles deposited onto its surfaces with minimal binary coalescence. Soft agglomerates prepared from 10:18 weight ratio of nanoparticles to nanoparticle aggregation vehicle using 1% chitosan solution concentration reduced the propensity of premature drug release of nanoparticles in the upper gastrointestinal region. Soft agglomerates reduced early drug release of cancer chemotherapeutics and was responsive to intracapsular sodium alginate coat to further sustain drug release. The soft microagglomerates are a viable dosage form in colon-specific drug delivery. Further study will focus on investigating intracapsular-coated soft agglomerates in vivo pharmacokinetics and pharmacodynamics behaviours with respect to local colorectal cancer.
APA, Harvard, Vancouver, ISO, and other styles
6

Nakamura, Jun, Yoshihiko Kitajima, Keita Kai, Kazuyoshi Hashiguchi, Masatsugu Hiraki, Hirokazu Noshiro, and Kohji Miyazaki. "Abstract LB-376: Hypoxia-inducible factor-1 alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-fluorouracil chemotherapy." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-lb-376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Delbaldo, C., D. Serin, M. Mousseau, S. Greget, B. Audhuy, F. Priou, J.-F. Berdah, E. Teissier, E. Quinaux, and P. Piedbois. "Abstract P5-10-05: A Phase III Adjuvant Randomized Trial of 6 Cycles of 5-Fluorouracil - Epirubicine-Cyclophosphamide (FEC100) Versus 4 FEC 100 Followed by 4 Taxol (FEC-T) in Node Positive Breast Cancer Patients (Trial B2000)." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p5-10-05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Yonemori, K., S. Ohsumi, S. Takao, Y. Tokuda, Y. Ito, K. Nakagami, M. Takahashi, et al. "Abstract P1-13-09: Long-term follow-up of two randomized controlled trials (N-SAS-BC01 trial and CUBC trial) comparing oral tegafur-uracil (UFT) versus classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as adjuvant therapy in early breast cancer." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p1-13-09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Brandberg, Yvonne, Nils-Olof Bengtsson, Richard Greil, Volker Möbus, Per Malmström, Hemming Johansson, Harald Andersson, et al. "Abstract P1-13-12: [bold]The adjuvant PANTHER study - A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxel – First report on q." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p1-13-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Masuda, N., N. Sato, K. Higaki, M. Kashiwaba, N. Matsunami, T. Takano, J. Yamamura, et al. "Abstract P1-14-08: A prospective multicenter randomized phase II neo-adjuvant study of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) followed by docetaxel, cyclophosphamide and trastuzumab (TCH) versus TCH followed by FEC versus TCH alone, in patients (pts) with operable HER2 positive breast cancer: JBCRG-10 study." In Abstracts: Thirty-Fifth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 4‐8, 2012; San Antonio, TX. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/0008-5472.sabcs12-p1-14-08.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Adjuvant 5-Fluorouracil' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography